cosmonauts.globacap.com Open in urlscan Pro
2606:4700:10::6816:38a1  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Log In
Sign up
Log In
Sign up

Celex Oncology
Summary
Details
Team
Contact Us
Documents
Investment Summary
Terms

Invest
1.03m shares
Issuer: Celex Oncology Innovations Limited
share Price : £4.84
Target:
GBP 5.00m
shares Sold: 206.61k
20.00%

Company Overview


ABOUT US

Celex is a UK-based Biotech company developing a treatment to improve the
survival prospects and quality of life for cancer patients. As a spin-off from
Imperial College, it captures ground-breaking work that has the potential to
turn cancer from a life-threatening disease to a chronic illness like high blood
pressure. Current data shows that our lead drug can reduce the risk of death by
60%* in three of the largest cancer forms - breast, colon and prostate. We’re
leading the way in reducing the harm caused by this invasive, destructive
disease.







HIGHLIGHTS

 * Our drug and treatments are protected by multiple patents




 * Proof of concept that it works in man based on 165 patients




 * Celex’s drugs turn cancer from a deadly to a chronic disease




 * Celex are seeking marketing approval based on existing human data  





PITCH DECK

Download





CONTACT US

Directly by email:




caf@celex-oncology.com







Or call us on:




+45 21 14 12 39







Linkedin:




www.linkedin.com/company/celex-oncology-ltd/







* https://www.medrxiv.org/content/10.1101/2022.12.16.22283520v2

Financial Promotion Approver

Globacap Limited

FRN

811661

Approval Date/Time

27/02/2023 10:58

London, UK
Oncology
<10
celexoncology.com
Exec Team
Carsten Faltum
Director & COO
Mustafa Djamgoz
CSO
Laurence Cohen
General Counsel


IMPORTANT INFO

Investing carries risks, including loss of capital and illiquidity. Please read
our 
Risk Warnings
 before making any investment decision.

The funding rounds available on the Globacap platform have been approved by
Globacap Limited as a financial promotion. In approving financial promotions,
Globacap concludes that the information for any one promotion, taken as a whole,
complies with the financial promotion rules, and among other things that it is
fair, clear, and not misleading, meaning it has been reviewed for evidence of
accuracy. However you should note that Globacap reviews evidence received from
the business raising funds, and does not audit that information, which means
that Globacap may not be able to identify forged or altered evidence. You should
also note that in the case of aspirational statements, the nature of the type of
business presented on the Globacap platform is such that are likely to have high
ambitions, Globacap does not hold a view as to whether such statements are
likely.

Globacap Limited is authorised and regulated by the Financial Conduct Authority
(No. 811661).

In addition to any of its regulated activities, Globacap may provide certain
services or undertake certain activities from time to time which are not
regulated by the FCA.

 * Risk Warnings
 * Terms & Conditions
 * Privacy Policy